April, 2024
April 2024
Pat Garcia-Gonzalez: It is time to re-think advanced breast cancer
Nov 14, 2023, 04:01

Pat Garcia-Gonzalez: It is time to re-think advanced breast cancer

Pat Garcia-Gonzalez, Chief Executive Officer at The Max Foundation, shared a post by The Max Foundation on LinkedIn, adding:

”It is time to re-think advanced breast cancer. Nowadays there are impactful therapies available in high income countries that provide people diagnosed with ABC good quality of life and precious time. Yet, in too many places the word ‘advanced’ is thought by many as a lost cause not worthy of investment. Never mind that in many LMICs 70 percent of breast cancer patients may present with advanced disease.

These are our sisters, our mothers, our daughters, our friends and their lives matter, and time with their families is the most precious gift we can give someone we love. This week for the first time, women in Mozambique diagnosed with HR+ HER2- advanced breast cancer have access to these therapies. I am deeply grateful to everyone who has made this possible including the health care team at Maputo General Hospital, Tanner Pharma Group, and the members of our Humanitarian PACT, the ABC Global Alliance, the American Society for Clinical Pathology (ASCP), Novartis, and The Max Foundation. Together we can prevent unnecessary suffering and premature death in LMICs and because we can, we must. As we approach the holiday season, this week we celebrate the power of collaboration and the gift of time with our loved ones.”

Quoting The Max Foundation’s post:

”We are thrilled to announce that women with advanced breast cancer in Mozambique have started treatment! This is a groundbreaking achievement made possible through our Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT), which aims to increase access to treatment, care, and support at no cost to patients in low- and middle-income countries.

We are grateful to our Humanitarian PACT for Advanced Breast Cancer partners ABC Global Alliance, American Society for Clinical Pathology (ASCP), Cepheid, and Novartis for their commitment and collaboration to make this possible. Together, we are working to expand this program to eight more countries and to reach more people living with advanced breast cancer worldwide.”

For more information click here.
Source: Pat Garcia-Gonzalez/LinkedIn and The Max Foundation/LinkedIn